Coforge, Nykaa, Sona BLW, Gland Pharma: Check midcap and smallcap stocks at 52-week highs

The Indian stock market staged a sharp rally on Thursday, November 5, as investors focused on the correction in global crude prices, a pullback in bond yields, massive FII buying interest and improving sentiment about the West Asia conflict.

The optimism was further reinforced by broadly strong earnings from Indian companies, adding to the momentum behind the market’s spectacular surge.

The broader market was also trading positive, with both the NIFTY Midcap 100 and Nifty Smallcap 100 rising over 2% and 1.4%, respectively.

On the midcap space, as many as nine stocks hit their 52-week high levels, while 4 stocks from the smallcap index touched their one-year high level.

The SENSEX jumped as much as 2.7% to an intra-day high of 79,465.03. Meanwhile, the NIFTY50 reached the session’s high of 24,579.90, gaining 2.5%.

NIFTY Midcap 100 stocks at 52-week high

The consumer goods player on Thursday reported its earnings for the July-September quarter of the 2026-27 financial year (Q2 FY27), posting a 25.66% year-on-year (YoY) surge in its consolidated net profit to ₹489.35 crore. In the corresponding period of the preceding fiscal year, it had logged a profit of ₹389.43 crore, according to a regulatory filing.

Its revenue from operations advanced 19.5% YoY to ₹7,380.05 crore during the quarter under review, compared with ₹6,174.03 crore in the second quarter of the 2025-26 fiscal year (Q2 FY26).

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹701 crore in Q2 FY27, registering a 28% YoY growth from ₹548 crore in the year-ago period.

Its EBITDA margin rose 63 basis points (bps) YoY to 9.5% for the reporting period, as against 8.9% in the September quarter of FY26, despite commodity and currency headwinds.

Lenskart Solutions shares jumped 10.5% to hit a fresh all-time high of ₹762.75 apiece on Thursday as investors cheered Q2 FY27 earnings. For the quarter ended September 2026, the company’s revenue from operations jumped 32.5% YoY to ₹2,845 crore, led by volume growth and premiumisation.

The Indian business surged 35.3% YoY, and the international business surged 29.5% YoY (~23.5% in constant currency). At the operating level, the company’s EBITDA surged 46.6% YoY to ₹624 crore, and the margin expanded by 21.9%. The net profit more than doubled to ₹232 crore, up from ₹112 crore in the corresponding quarter last year.

The FMCG major reported a growth of 31% in its consolidated net profit at ₹550 crore for September. The company’s net profit in the same quarter in the previous fiscal year was ₹420 crore.

Its revenue from operations for Q2 FY27 stood at ₹3,897 crore, increasing 13% YoY from ₹3,450 crore in the same period of the previous fiscal year. On an operational level, Marico’s EBITDA grew 27% to ₹709 crore in Q2 FY27 as against ₹560 crore in Q2 FY26. Its EBITDA margin expanded to 18.19% for the reporting quarter in contrast to 16.23% YoY, the highest in 50 quarters.

The company’s revenue from operations increased 28% year-on-year (YoY) to ₹3,006 crore as compared to ₹2,346 crore in Q2 FY26. Nykaa’s consolidated gross merchandise value (GMV) grew 30% annually to ₹6,151 crore. 

On the operational level, Nykaa’s EBITDA stood at ₹263 crore, marking a jump of 66% from ₹158 crore in the corresponding quarter of the previous fiscal year. The company’s EBITDA margin also expanded to 8.75% in contrast to 6.75% YoY. 

NIFTY Smallcap 100 stocks at 52-week high

Singh shared that the company would continue investing across all its three business lines, adding that it had introduced three new products during the September quarter.

"Annual investment is currently around ₹500-600 crore. This should increase as we grow over the decade," he said. Singh said investments would cover multiple areas, including R&D, capacity additions, capability additions and new processes, with the company focusing on developing entirely new products.

Dr Lal PathLabs’ consolidated profit after tax (PAT) increased 27.39% to ₹193.9 crore for the September quarter on the back of a rise in revenues. The diagnostics firm reported a profit after tax (PAT) of ₹152.2 crore in the July-September period of the last fiscal year.

Its total revenue increased to ₹908.2 crore for the period under review, as against ₹755.4 crore in the year-ago period, Dr Lal PathLabs said.

The company’s total expenses also rose to ₹647.6 crore in the July-September period, from ₹551.8 crore a year earlier.